Over a span of five-and-a-half months this year, 3.5% of the more than 11,000 clinical trials funded by the U.S. NIH had ...

About a month after rolling out positive phase I/II data with its candidate for metastatic, castrate-resistant prostate ...

While Europe’s biotech sector continues to face headwinds, med tech appears to be weathering the storm more effectively. Uncertainty in the U.S., heightened competition from China and a persistent ...

Fresh cash infusions are on the way for European biotech after two leading venture capital firms announced large new funds.

DNA damage response specialist Artios Ltd. has closed an oversubscribed $115 million series D after delivering positive phase ...

Mitorx Therapeutics Ltd. has raised £5.5 million (US$7.2 million) in a pre-series A round to advance its lead ...

The inhibition of PD-L1 and VEGF individually or in combination has shown efficacy across several solid tumor types, but not ...

Researchers from Arcus Biosciences Inc. described the antitumor efficacy of AB-801, an AXL inhibitor in several cancer models ...

The Medicare Wasteful and Inappropriate Service Reduction (WISeR) proposal is designed to tamp down on waste, fraud and abuse ...

Coave Therapeutics SA has nominated a lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple ...

Researchers from Tango Therapeutics Inc. presented preclinical efficacy data on TNG-260, an inhibitor of the co-repressor of repressor element-1 silencing transcription (CoREST) deacetylase complex, ...